- Home
- BSX vs GILD Comparison
BSX vs GILD Comparison
Compare BSX & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSX
- GILD
- Stock Information
- Founded
- BSX 1979
- GILD 1987
- Country
- BSX United States
- GILD United States
- Employees
- BSX N/A
- GILD N/A
- Industry
- BSX Medical/Dental Instruments
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSX Health Care
- GILD Health Care
- Exchange
- BSX Nasdaq
- GILD Nasdaq
- Market Cap
- BSX 157.6B
- GILD 144.1B
- IPO Year
- BSX 1992
- GILD 1992
- Fundamental
- Price
- BSX $105.55
- GILD $112.97
- Analyst Decision
- BSX Strong Buy
- GILD Buy
- Analyst Count
- BSX 22
- GILD 23
- Target Price
- BSX $118.32
- GILD $115.68
- AVG Volume (30 Days)
- BSX 5.9M
- GILD 6.3M
- Earning Date
- BSX 10-22-2025
- GILD 08-07-2025
- Dividend Yield
- BSX N/A
- GILD 2.80%
- EPS Growth
- BSX 36.90
- GILD 496.80
- EPS
- BSX 1.68
- GILD 5.01
- Revenue
- BSX $18,494,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- BSX $19.75
- GILD $2.01
- Revenue Next Year
- BSX $10.98
- GILD $4.03
- P/E Ratio
- BSX $62.79
- GILD $22.54
- Revenue Growth
- BSX 21.44
- GILD 3.81
- 52 Week Low
- BSX $79.53
- GILD $77.74
- 52 Week High
- BSX $108.94
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- BSX 53.71
- GILD 44.63
- Support Level
- BSX $104.80
- GILD $113.81
- Resistance Level
- BSX $107.01
- GILD $118.13
- Average True Range (ATR)
- BSX 1.53
- GILD 2.03
- MACD
- BSX 0.18
- GILD -0.79
- Stochastic Oscillator
- BSX 72.91
- GILD 8.52
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).